Immunotherapy innovation: Moon Shots effort aims natural killer cells at cancer
MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches to our patients quickly, safely and effectively. The platform is one of the research engines driving MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.
By working closely...
Moon Shot deploys policy help, education and clinical trial innovation against tobacco use
November is Lung Cancer Awareness Month, and the third Thursday of each November is designated by the American Cancer Society as the Great...
Moon Shot promotes efforts to prevent, quickly detect pancreatic cancer
Each year in the U.S., more than 50,000 people will be diagnosed with pancreatic cancer, which ranks around the 10th most common cancer type...
TRACTION accelerates translation of discoveries into new clinical approaches
Despite major recent advances in oncology drug discovery, including the development of innovative targeted, immune and cell-based therapies, there remain many opportunities to improve outcomes for patients with cancer. Some may not benefit from available treatments, and others may have highly aggressive or drug-resistant cancers that require new options.
As part of MD Anderson’s commitment to bring our patients the most effective...
APOLLO’s high-quality longitudinal samples empower cancer investigators
Cancer’s ability to evolve in response to treatment and develop resistance to available therapies is one of the most significant challenges...
Moon Shot rises to challenge of glioblastoma
Glioblastoma (GBM) is not among the most commonly diagnosed cancers in the U.S., but it can certainly be among the most devastating. Of the...
Lung cancer targeted therapy hits common HER2 variants across cancers
Building upon the foundational discovery that the targeted therapy poziotinib is a potent and selective inhibitor of specific EGFR and HER2...
Breast, ovarian cancer trials find targeted therapies provide benefit over chemotherapy
Results from two The University of Texas MD Anderson Cancer Center-led clinical trials indicate that targeted therapies led to significant...
AML drug may be good for KRAS-driven pancreatic cancer, computer-aided drug discovery finds
Repurposing FDA-approved therapies is a cost-effective way to bring new treatments to patients in need, but identifying those drugs with benefits...
Moon Shot confronts challenges of multiple cancers driven by HPV
According to the Centers for Disease Control and Prevention, the human papillomavirus is responsible for roughly 33,700 new cancer cases each...
MD Anderson advances novel therapeutic antibody into AML clinical trials
Leukemia researchers at The University of Texas MD Anderson Cancer Center, working collaboratively with the Therapeutics Discovery division...